Michael F. Sharp

Fanconi Anaemia E3 Ligase complex activity is regulated by a druggable metabolite binding site in FANCX

The paper identifies a druggable metabolite binding site in the FA E3 ligase complex that inhibits its activity and selectively kills BRCA1-deficient cells.

Multi-lineage natural gene therapy mediated by embryonic triploid mosaicism in the context of Fanconi anaemia

A patient with Fanconi anemia developed triploid hematopoietic stem cells that lacked the disease phenotype, enabling sustained hematopoiesis through restored DNA repair.

Differential PARP inhibitor responses in BRCA1-deficient and resistant cells in competitive co-culture

This paper introduces a competitive co-culture assay to detect synthetic lethal effects of PARP inhibitors in BRCA1-deficient cells and identifies differences in PARP inhibitor resistance.

Clinical and Genetic Spectrum of Fanconi Anaemia in Australia and New Zealand.

This study investigates the clinical and genetic spectrum of Fanconi anaemia in Australia and New Zealand, finding a correlation between testing rates and case detection, and highlighting increased susceptibility to HNSCC.